Plain-English translation of NCT05284552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing tinzaparin, a blood-thinning medication, in women with advanced ovarian cancer who are receiving chemotherapy before surgery. Half of the participants will receive daily injections of this medication while undergoing chemotherapy, and half will not receive it. The study measures how the medication affects various blood markers and inflammation proteins in the body.
Cancer can increase the risk of dangerous blood clots, and chemotherapy further raises this risk. This trial is exploring whether giving this medication during chemotherapy might help prevent clots and reduce harmful inflammation, potentially improving outcomes for women with advanced ovarian cancer.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital before chemotherapy starts and before each of your chemotherapy cycles to have blood drawn for testing. If randomly assigned to receive the medication, you would give yourself a daily injection under the skin for about 5–7 months while receiving chemotherapy and continuing through surgery recovery. You would also have blood samples taken before surgery and three weeks after your final chemotherapy dose. The entire study lasts several months, coordinated with your standard cancer treatment plan.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Sweden